Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised

by Zacks Equity Research

BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 16.67% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi

by Zacks Equity Research

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.

Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

by Zacks Equity Research

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BMRN or MYGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BMRN vs. MYGN: Which Stock Is the Better Value Option?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)

by Zacks Equity Research

BioMarin (BMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

by Zacks Equity Research

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

by Zacks Equity Research

BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.

Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com featured highlights include Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo

by Zacks Equity Research

Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo are part of the Zacks Screen of the Week article.

Swayta Shah headshot

Bet on These 5 Stocks With Upgraded Broker Ratings Right Now

by Swayta Shah

Brokers have deeper insights into stocks and the macroeconomic backdrop. One must follow broker rating upgrades to pick stocks like WWW, BMRN, DDOG, PGR & KVYO.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is the Options Market Predicting a Spike in BioMarin (BMRN) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

by Zacks Equity Research

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

Here's Why You Should Invest in BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.